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osting by EAbstract Introduction: Cardiovascular disease is an increasingly recognized contributor to excess
morbidity and mortality in psoriatic arthritis (PsA). Traditional cardiovascular risk factors do not
adequately account for the extent of cardiovascular disease in PsA.
Aim of the work: To examine the prevalence of subclinical atherosclerosis in patients with PsA to
emphasize the potential role of serum uric acid on endothelial dysfunction, as an early predictor for
atherosclerosis in PsA patients.
Patients and methods: This study included 60 PsA patients as well as 60 age and sex matched
healthy controls. Assay of serum uric acid, interleukin-6 (IL-6) and soluble intercellular adhesion
molecule-1 (sICAM-1) was done for all patients and controls. Patients were subjected to psoriasis
area severity index (PASI) and assessment of disease activity. Patients and controls underwent bra-
chial ﬂow-mediated dilatation (FMD) assessment by color duplex sonography to determine endo-
thelial dysfunction as well as extracranial carotid arteries assessment by high-resolution B-modeHassan Aﬂaton Street, Golf
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84 S.E. Ibrahim et al.ultrasound to measure the common carotid intima-media thickness (CIMT) and the detection of
atheromatous plaques.
Results: PsA patients have a high signiﬁcant difference in CIMT, FMD of the brachial artery
and mean levels of serum uric acid compared to healthy controls (p< 0.001). PsA patients with
hyperuricemia have a high signiﬁcant difference in CIMT and FMD of the brachial artery than
those with normal serum uric acid. Serum uric acid levels showed a high signiﬁcant positive corre-
lation with each of CIMT, disease duration, markers of inﬂammation (ESR, CRP, IL-6, sICAM-1),
disease activity score in 28 joints (DAS 28) and PASI (r= 0.71, 0.893, 0.956, 0.858, 0.853, 0.877,
0.907, 0.847, respectively, as p< 0.001). A high signiﬁcant negative correlation was found between
serum uric acid levels and FMD of the brachial artery as r= 0.634, p< 0.001.
Conclusion: Patients with PsA have a high prevalence of subclinical atherosclerosis dependent on
serum uric acid, suggesting that chronic systemic inﬂammation and endothelial dysfunction appear
to be the link between asymptomatic hyperuricemia and atherosclerosis. Therefore, proper control
of serum uric acid may play a preventive role in the development of atherosclerosis in PsA patients.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Psoriasis is a hereditary, chronic inﬂammatory skin disorder
and psoriatic arthritis (PsA), which has been deﬁned as an
inﬂammatory arthritis associated with psoriasis, appears to
be linked to an increased cardiovascular (CV) mortality and
morbidity [1].
Atherosclerosis is a multifocal, immune-inﬂammatory dis-
ease affecting the medium and large arteries. There is growing
evidence that, in addition to traditional risk factors, vascular
wall inﬂammation plays a key role in the pathogenesis of vas-
cular diseases and atherosclerosis [2].
An important step forward in our understanding of
whether PsA is associated with increased cardiovascular mor-
tality and morbidity may be to determine the presence of sub-
clinical data of atherosclerotic disease in patients without overt
cardiovascular complications or traditional cardiovascular risk
factors. At present, several noninvasive imaging techniques of-
fer an opportunity to study the relationship of surrogate mark-
ers to the development of atherosclerosis [3]. One of these
surrogate markers is the presence of endothelial dysfunction,
considered as the earliest stage of atherosclerosis [4]. More-
over, an increased incidence of endothelial dysfunction has
been observed in PsA patients without classic risk factors [3].
Endothelial function can be noninvasively evaluated by post
occlusion ﬂow-mediated dilation (FMD%) of the brachial ar-
tery [5]. FMD has been widely used, as a functional parameter
of endothelium, and early atherosclerotic morphological wall
changes in different arterial walls [6]. Impaired ﬂow-mediated
dilatation (FMD) assessed by ultrasonographic determination
of reduced vasodilator inﬂuence during reactive hyperemia is
now considered a quite reliable indicator of endothelial dys-
function in human resistance arteries and is related to cardio-
vascular events [7].
Intima-media thickness of carotid arteries (CIMT) mea-
sured by Doppler ultrasound is considered to be a reliable mar-
ker of early generalized atherosclerosis while the presence of
atherosclerotic plaques indicates more manifested atheroscle-
rosis [8].
Hyperuricemia (HU) has been associated with an increased
incidence of CV events, and HU is a common characteristic of
patients with PsA [9]. Therefore, it is important to study thepotential implication of serum uric acid and HU in the
development of CV disease in patients with PsA to establish
whether a correlation exists between serum uric acid levels
and subclinical atherosclerosis in PsA without clinically evi-
dent CV disease.
Therefore, the aim of this work was to examine the preva-
lence of subclinical atherosclerosis in patients with PsA to
emphasize the potential role of serum uric acid on endothelial
dysfunction, as an early predictor for atherosclerosis in PsA
patients.
2. Patients and methods
The present case control study was carried out on 60 PsA pa-
tients who attended the outpatient clinics of Rheumatology &
Rehabilitation and Dermatology Departments of Ain Shams
University Hospital. PsA patients fulﬁlled the Moll and
Wright criteria [10]. Sixty healthy volunteers matching in age
and sex served as a control group. Written informed consent
was obtained from every patient and control. The study was
approved by Ain Shams medical ethics committee.
We excluded from the study patients with evidence of CV
disease or received drugs affecting the CV system, previous
myocardial infarction, patients with hypertension (deﬁned by
blood pressureP 140/90 mmHg or using antihypertensive
drugs), diabetes mellitus, renal failure, body mass in-
dex > 30 kg/m2, smokers or had stopped smoking for less
than two years, history of hyperlipidemia, stoke, transient
ischemic attacks, active infectious diseases and malignancy.
Nonsteroidal anti-inﬂammatory drugs, including cyclo-
oxygenase-2 inhibitors were discontinued in all patients at least
30 days before vascular examination. In this study, 46 patients
were receiving methotrexate either alone or in combination
with sulfasalazine or oral cyclosporine, 14 patients were being
treated with prednisone (65 mg/day).
All patients and controls were subjected to:
 Full medical history taking.
 Thorough clinical examination.
 Assessment of psoriasis area and severity: The severity and
extent of psoriasis were assessed by the psoriasis area sever-
ity index (PASI) for each patient [11]. PASI is a composite
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and desquamation (D) in four anatomical sites: head (h),
upper extremities (u), trunk (t), and lower extremities (l)
roughly corresponding to 10%, 20%, 30% and 40% of
body surface area, respectively. The severity of erythema,
indurations and desquamation is assessed according to a 5
point scale where 0 = no symptoms, 1 = slight, 2 = mod-
erate, 3 = marked, and 4 = very marked. Area (A) is
assigned a numerical value based on the extent of the
lesions on the given anatomical sites where 1 6 10%,
2 = 10–29%, 3 = 30–49%, 4 = 50–69%, 5 = 70–89%,
6 = 90–100%. The area score (AS) was determined by the
sum of area scores of given anatomical sites multiplied by
the corresponding ratio of body surface area. PASI was
determined using the following calculation:
PASI ¼ 0:1ðEh þ Ih þDhÞAh þ 0:2ðEu þ Iu þDuÞAu þ 0:3ðEt
þ It þDtÞAt þ 0:4ðEl þ Il
þDlÞAl ðTotal score of 72Þ
 Disease activity was assessed using the disease activity score
in 28 joints (DAS 28) for PsA patients with predominant
peripheral arthritis [12]. The Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) was used to evaluate
the disease activity in patients with predominant axial dis-
ease [13].
Laboratory assessment:
– Routine laboratory investigations were done for all patients
and controls including erythrocyte sedimentation rate
(ESR) by Westergren method, complete blood count using
coulter method and C- reactive protein (CRP) quantita-
tively by latex technique.
– Serum total cholesterol, triglycerides levels, and low density
lipoproteins (LDL) were analyzed by enzymatic colorimet-
ric techniques to exclude hyperlipidemia. Fasting blood glu-
cose and serum creatinine levels were done to exclude
diabetes and renal failure.Table 1 Laboratory and radiological characteristics of patients and
Variables Patients (number = 60)
Mean SD
Age (years) 48.90 9.10
ESR (mm/h) 31.77 13.82
CRP (mg/l) 7.36 4.31
Serum uric acid (mg/dl) 5.75 1.77
IL-6 (pg/ml) 253.67 119.04
sICAM-1 (ng/ml) 633.37 139.32
Cholesterol (mg/dl) 138.5 25.39
Triglyceride (mg/dl) 131.62 27.85
HDL (mg/dl) 50.93 3.35
LDL (mg/dl) 119.60 10.49
CIMT (mm) 0.94 0.35
FMD% 3.02 0.84
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, IL-6: inter
carotid intima-media thickness, FMD: ﬂow-mediated dilatation of the
lipoprotein, SD: standard deviation.– Serum samples were investigated for the levels of pro-
inﬂammatory cytokine including interleukin-6 (R&D sys-
tems) and soluble intercellular adhesion molecule-1
(IMMUNOTECH, SAS-Marseille, Cedex 9, France) by
enzyme linked immunosorbent assay (ELISA). Serum uric
acid concentration was measured using a standard enzy-
matic assay (Randox, Antrim, UK). HU was deﬁned as
serum uric acid > 7 mg/dl in men and > 6.5 mg/dl in
women [9].
Radiological investigations:
– Patients and controls underwent brachial ﬂow-mediated
dilatation (FMD) assessment by color duplex sonography
(GE logic 7). The brachial artery was scanned by B-mode
ultrasonography in longitudinal axis just above the cubital
fossa with a linear probe frequency of 12 MHz. We used
the average diameter of three different measurements at
the basal and post hyperemia states [14]. FMD represents
the relative increase in brachial artery diameter during
hyperemia = (100 · post hyperemia diameter  basal
diameter/basal diameter)
– Patients and controls underwent extracranial carotid arter-
ies assessment by high-resolution B-mode ultrasound. The
ultrasonographic scan protocol was used to measure the
intima-media thickness in the common carotid artery in
mm and detection of the atheromatous plaques if present.
A cutoff value of 0.9 mm was taken for CIMT, patients
who had CIMT above this value were considered to have
atherosclerosis. Plaque was deﬁned as a localized thicke-
ning > 1.2 mm that did not uniformly involve the whole
artery [15].
Statistical analysis: Analysis of the data was done by IBM
computer using SPSS (statistical program for social science ver-
sion 12). Mean and standard deviation (SD) were used to de-
scribe quantitative variables. Number and percentage were
used for qualitative variables. Unpaired t-test was used to com-
pare quantitative variables, in parametric data (SD< 50%
mean). Correlation analysis (using Pearson’s method) was to
assess the strength of association between two quantitativecontrols.
Controls (number = 60) t p value
Mean SD
48.97 6.41 0.046 0.963
7.97 2.14 8.75 0.000
3.36 0.98 5.289 0.000
4.44 0.80 5.23 0.000
78.53 5.02 9.121 0.000
351.10 37.03 9.449 0.000
142.5 21.5 0.452 0.65
132.17 21.39 0.711 0.477
51.17 4.02 0.237 0.813
117.44 13.96 0.657 0.514
0.67 0.10 4.428 0.000
5.53 0.79 16.811 0.000
leukin-6, sICAM-1: soluble intercellular adhesion molecule-1, CIMT:
brachial artery, HDL: high density lipoprotein, LDL: low density
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deﬁnes the strength and direction of the linear relationship be-
tween two variables. Chi-square test was used to make the com-
parison between groups with qualitative variables. Linear
regression test was used to ﬁnd the relation between serum uric
acid and the studied parameters and to ﬁnd the early predictors
for serum uric acid.
3. Results
This study included 60 PsA patients. They were 16 females
(26.7%) and 44 males (73.3%). Their ages ranged from 30 to
63 years with a mean of 48.9 ± 9.1. Their disease duration
ranged from 1.5 to 17 years with a mean of 9.7 ± 4.13. Disease
activity in PsA patients with peripheral arthritis was assessed
by DAS 28 which ranged from 0.77 to 7.50 with a mean of
5.15 ± 2.02. The BASDAI was used to assess the disease activ-
ity for patients with predominant axial involvement, it ranged
from 3.6 to 6.2 with a mean of 4.39 ± 1.02. The PASI ranged
from 2.2 to 54.2 with a mean of 27.5 ± 17.5. Sixty healthy
individuals, matching in age and sex, served as a control
group. They were 18 females (30%) and 42 males (70%). TheirFigure 1 (a) B-mode ultrasonography showing intima-media
thickness of the right common carotid artery (1.1 mm in
thickness). (b) B-mode ultrasonography showing soft tissue
atheromatous plaque at the left common carotid artery (2.1 mm
in thickness).ages ranged from 39 to 62 years with a mean of 48.97 ± 6.41.
PsA frequently evolved from oligoarticular to polyarticular
over the course of the disease. Therefore, at the time of the
study four (6.6%) of the patients presented with distal joint
disease, 15 (25%) had oligoarthritis involving 6 4 joints, 21
(35%) had polyarthritis affectingP 5 joints, 1 (1.6%) had
arthritis mutilans, and 19 (31.6%) had spondyloarthritis.
The laboratory and radiological characteristics of patients
and controls are summarized in Table 1.
There was a statistically highly signiﬁcant difference be-
tween PsA patients and controls regarding mean values of
CIMT and FMD of the brachial artery as p< 0.001(Figs. 1
and 2). A statistically highly signiﬁcant difference was found
between PsA patients and controls regarding serum levels of
uric acid, interleukin-6 (IL-6) and soluble intercellular adhe-
sion molecules-1 (sICAM-1) (p< 0.001).
On comparing PsA patients with high serum uric acid levels
to patients with normal serum uric acid levels, there was a sta-
tistically highly signiﬁcant increase in CIMT, presence of car-
otid plaques and impairment of FMD in PsA patients with
HU (p< 0.001). There was a statistically highly signiﬁcant dif-
ference in serum levels of ESR, CRP, IL-6 and sICAM-1 in
PsA patients with HU (p< 0.001) (Table 2).
There was a statistically highly signiﬁcant correlation be-
tween mean serum levels of uric acid and CIMT in PsA pa-
tients as r= 0.71, p< 0.001 (Fig. 3). A statistically highly
signiﬁcant negative correlation was found between mean ser-
um levels of uric acid and FMD of the brachial artery as
r= 0.634, p< 0.001 (Fig. 3). A highly signiﬁcant correla-
tion was found between mean serum levels of uric acid and
each of disease activity score of PsA patients with predominant
peripheral disease (DAS 28), disease severity (PASI) and dis-
ease duration as r= 0.907, 0.847 and 0.893, respectively, as
p< 0.001.There was a high signiﬁcant correlation between
mean serum levels of uric acid and markers of inﬂammation
(ESR, CRP, IL-6, sICAM-1) as r= 0.956, 0.858, 0.853 and
0.877, respectively.
There was a high signiﬁcant increase in the presence of pla-
ques in PsA patients with HU compared to those with normal
serum uric acid (Table 3).Figure 2 Comparison between PsA patients and controls
regarding CIMT and FMD.
Table 2 Characteristics of PsA patients with HU compared to those with normal serum uric acid.
Variables Serum uric acid (number = 60 patients) t p value
Normal (number = 44) High (number = 16)
Mean SD Mean SD
Age (years) 46.57 9.61 45.33 5.47 1.432 0.157
Duration (years) 8.37 3.80 12.81 3.13 4.356 0.000
DAS28 3.64 2.10 7.52 0.92 6.128 0.000
BASDAI 4.50 0.96 5.80 0.41 0.236 0.81
PASI 18.48 12.46 48.67 4.56 9.952 0.000
ESR (mm/h) 25.10 10.81 47.33 3.79 8.472 0.000
CRP (mg/l) 5.03 2.44 12.79 2.36 11.389 0.000
Serum uric acid (mg/dl) 5.06 1.68 7.37 0.36 5.975 0.000
IL-6 (pg/ml) 189.05 73.81 404.44 40.70 5.972 0.000
sICAM-1 (ng/ml) 561.29 96.24 801.56 47.30 5.908 0.000
CIMT (mm) 0.75 0.17 1.39 0.24 6.03 0.000
FMD% 3.45 0.5 1.85 0.13 12.55 0.000
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS 28: disease activity score 28, BASDAI: bath ankylosing spondylitis disease
activity index, PASI: psoriasis area severity index, IL-6: interleukin-6, sICAM-1: soluble intercellular adhesion molecule-1, CIMT: carotid
intima-media thickness, FMD: ﬂow-mediated dilatation of the brachial artery.
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association between serum uric acid and disease duration as
t= 2.175, p< 0.05 and a high signiﬁcant association with
ESR as t= 8.4, p< 0.001, while there was no signiﬁcant
association between serum uric acid and the rest of the studied
parameters.
A highly signiﬁcant correlation was found between CIMT
and each of FMD of the brachial artery, disease duration,
ESR, CRP, IL-6 and sICAM-1 as r= 0.911, 0.661, 0.853,
0.936, 0.938, 0.919, respectively (p< 0.001). On performing
linear regression test for early predictors of atherosclerosis,
there was a signiﬁcant high association between CIMT and
serum uric acid levels as t= 4.32, p< 0.001.
4. Discussion
The present study demonstrates that PsA patients without clin-
ically evident cardiovascular disease have a high prevalence of
subclinical atherosclerosis and presence of plaques in the form
of increased carotid artery intima-media thickness and de-
creased FMD of the brachial artery compared with matched
controls. Our results agreed with those of Eder et al. [16] and
Gonzaley-Juanaty et al. [17] who denoted increased CIMT in
PsA patients without history of CV events or traditional risk
factors. Karadag et al. [5] supported our results as they found
that the impairment of FMD of the brachial artery was prom-
inent in patients with psoriatic arthritis compared with psoriat-
ic patients and controls.
One of the recent advances in understanding the pathogen-
esis of atherosclerosis is the recognition of the inﬂammatory
nature of atherosclerotic lesions. Inﬂammatory mechanisms
have been demonstrated in all stages of atherogenesis including
induction, progression and rupture of plaque [18]. In disorders
that are inﬂammatory in nature, the chronic inﬂammatory
state per se has been linked to acceleration in the atheroscle-
rotic process. The existence of this link is supported by the in-
creased incidence of CV disease observed in disorders such as
systemic lupus erythematosus and rheumatoid arthritis [19].
Inﬂammation promotes endothelial cell activation, which is
characterized by the loss of vascular integrity, increasedexpression of leukocyte adhesion molecules, change in pheno-
type from antithrombotic to thrombotic, production of several
cytokines, and up-regulation of major histocompatibility com-
plex HLA class II molecules. Also, chronic inﬂammation can
promote insulin resistance and oxidation, which also contrib-
ute to the development of endothelial dysfunction [20].
Ramonda et al. [18] had demonstrated the importance of
inﬂammatory mediators within atherosclerotic plaques, sug-
gesting that chronic inﬂammation acts independently or syner-
gistically with other factors. Moreover, Kimhi et al. [21] found
a correlation between CIMT and each of ESR and CRP.
Our study supported this hypothesis as we found a high sig-
niﬁcant correlation between CIMT and each of ESR, CRP, IL-
6 and sICAM-1. IL-6 is a major B-cell stimulatory factor in-
volved in the antibodies production [22]. IL-6, either locally
generated by cells with atherosclerotic lesion or released into
circulation, may heighten atherogenesis. IL-6 promotes endo-
thelial smooth muscle cell proliferation and migration as well
as recruitment and activation of inﬂammatory cells, thereby
perpetuating vascular inﬂammation [23]. Soluble ICAM-1 is
over-expressed as a result of endothelial dysfunction, and
thereafter released as measurable forms into the circulation,
representing laboratory markers for inﬂammation and activa-
tion of endothelial cells [24]. It is likely that detection of these
markers will have a predictive value for the development of
clinical atherosclerotic disease [25].
Van Doornum et al. [26] found that FMD of the brachial
artery provides valuable insights in early atherogenesis and
an impaired FMD of the brachial artery has been demon-
strated in asymptomatic individuals with established cardio-
vascular risk factors as well as it correlates with the severity
and extent of atherosclerosis. They suggested that impaired
brachial FMD might indicate an early functional abnormality
of the arterial system in the preclinical phase of vascular
disease.
A possible explanation for the association between PsA and
endothelial dysfunction is the presence of chronic inﬂamma-
tion that occurs because of the persistent secretion of tumor
necrosis factor-alpha and the other pro-inﬂammatory cyto-
kines such as IL-6, which precipitates PsA. Chronic systemic
Figure 3 (a) Correlation between serum uric acid levels and
CIMT in PsA patients (r= 0.71). (b) Correlation between serum
uric acid levels and FMD of the brachial artery in PsA patients
(r= 0.634).
Table 3 Percentage of plaques in PsA patients with asymp-
tomatic hyperuricemia.
Serum uric acid (mg/dl) Plaque v2 p value
Negative Positive
Normal
No. 44 0 41.250 0.000
% 91.70 0.00
High
No. 4 12
% 8.30 100.00
No. = number.
88 S.E. Ibrahim et al.inﬂammation induces endothelial dysfunction that plays a sig-
niﬁcant role in the development of atherosclerosis and appearsto be the link between PsA and atherosclerosis [27]. Endothe-
lial dysfunction therefore seems to be a systemic vascular
process that not only mediates the development of atheroscle-
rotic plaque, but in addition modulate its clinical course [28].
Our results revealed a signiﬁcant correlation between
CIMT and disease duration. This came in agreement with
Gonzaley-Gay et al. [29] and Contessa et al. [30] who denoted
that prolonged disease duration in PsA patients with this
chronic inﬂammatory disease may promote the development
of accelerated atherogenesis. These results may be interpreted
by Sattar et al. [31], who pointed that even during quiescent
phase of rheumatoid arthritis (RA), systemic levels of cyto-
kines or their regulatory components often remain dysregu-
lated compared with non-RA individuals and as such will
continue to promote vascular disease. This may also be the
case for individuals with PsA.
Our study demonstrated an increase in CIMT and impair-
ment of FMD of the brachial artery in PsA with HU compared
to those with normal serum uric acid levels. We found a signif-
icant correlation between serum uric acid levels and inﬂamma-
tory markers, such as ESR, C-reactive protein, IL-6 and
sICAM-1 levels. Our results were supported by Gonzaley-
Gay et al. [29] who found a potential role for serum uric acid
as an independent risk factor for accelerated atherosclerosis
found in PsA patients. Ruggiero et al. [32] found in their study
a signiﬁcant correlation between uric acid and inﬂammatory
markers, such as C-reactive protein, interleukin and tumor
necrosis factor levels. HU is a common characteristic of pa-
tients with PsA [9]. Therefore, these data suggest that uric acid
is not only a marker of the catabolic rate, but it may also be
actively involved in the inﬂammatory process. The enzymatic
effect of xanthine oxidase during tissue ischemia is the produc-
tion of reactive species of oxygen (ROS) and uric acid. ROS
can induce endothelial dysfunction by reducing the bioavail-
ability of nitric oxide. Uric acid presents potent antioxidant
properties and could counteract the generation of ROS [33].
However, there is also evidence that hyperuricemia per se im-
pairs endothelial dependent vasodilation by reduction in NO-
synthase in animal experiments [33]. Consequently; uric acid
could be a new potential marker of microvascular endothelial
dysfunction in these patients [34].
In conclusion, patients with PsA have a high prevalence of
subclinical atherosclerosis dependent on serum uric acid, sug-
gesting that chronic systemic inﬂammation and endothelial
dysfunction appear to be the link between asymptomatic
hyperuricemia and atherosclerosis. Consequently, uric acid
could be a new potential marker of microvascular endothelial
dysfunction in these patients. Therefore, proper control of ser-
um uric acid may play a preventive role in the development of
atherosclerosis in PsA patients.Conﬂict of interest
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